Meeting
2013 Gastrointestinal Cancers Symposium
Neoadjuvant capecitabine and oxaliplatin (XELOX) with bevacizumab for locally advanced rectal cancer.
Authors
Junichi Hasegawa
Department of Surgery, Osaka Rosai Hospital
Junichi Hasegawa , Tsunekazu Mizushima , Ho Min Kim , Yasuhiro Miyake , Hiroyoshi Takemoto , Hiroshi Tamagawa , Shingo Noura , Masayuki Ohue , Makoto Fujii , Yuichiro Fujie , Hirofumi Ota , Takeshi Kato , Mutsumi Fukunaga , Ichiro Takemasa , Masataka Ikeda , Hirofumi Yamamoto , Mistugu Sekimoto , Riichiro Nezu , Yuichiro Doki , Masaki Mori
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
000003219
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr566)
DOI
10.1200/jco.2013.31.4_suppl.566
Abstract #
566
Poster Bd #
E14
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2021 ASCO Annual Meeting
Long-term outcome of a phase III trial on neoadjuvant chemoradiation with capecitabine and irinotecan in patients with locally advanced rectal cancer: Updated results of the CinClare trial.
First Author: Ji Zhu
Poster
2021 Gastrointestinal Cancers Symposium
Short-course radiotherapy and subsequent CAPOX plus camrelizumab followed by delayed surgery for locally advanced rectal cancer: Short-term results of a phase II trial.
First Author: Zhenyu Lin
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang